Results

1–10 of 32 results for anti-VEGF therapy

Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
Anti-VEGF Therapy to Prevent Macular Fibrosis in Coats Disease
On Demand Cases, Courses, and Papers
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy (FELLOWS FORUM AWARD WINNER)
Lucy T Xu, MD
Annual Meeting Talks
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Carl J Danzig, MD
Annual Meeting Talks
2021
Intravitreal Anti-VEGF Therapy in Maintaining Long-term Driving Vision in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Parisa Emami Naeini, MD, MPH, FASRS
Annual Meeting Talks
2021